Polyethylene Glycol-3350

• Published in: The Turkish journal of gastroenterology 2018-01, Vol.29 (1), p.67
• Main Authors: Khan, Maqsood Ahmed, Patel, Kevin B, Nooruddin, Mohammed, Swanson, Garth, Fogg, Louis, Keshavarzian, Ali, Brown, Michael
• Format: Article
• Language: English
• Subjects: Analysis; Drug approval; Health aspects; Polyethylene glycol
• ISSN: 1300-4948
• DOI: 10.5152/tjg.2018.17536

Background/Aims: Polyethylene glycol (PEG)-3350, approved by Food and Drug Administration (FDA) only for constipation, combined with 1.9 L of sports drink (SD) (Gatorade[R]) and bisacodyl (B) is commonly used in outpatient practice for bowel preparation due to cited patient satisfaction and tolerability of this specific regimen. We aim to compare PEG-3350 (Miralax[R]) with PEG-AA-based (MoviPrep[R]) in terms of efficacy, patient satisfaction, and the effects of these two regimen on serum electrolytes. Materials and Methods: This study is a prospective, single-blinded, block randomized trial comparing single-dose PEG-3350+SD+B to split-dose 2-L PEG-AA in the outpatient endoscopy unit in patients undergoing colonoscopy. Basic metabolic profiles were checked on the day of randomization and on the day of procedure. Patients completed a survey on the day of procedure. Bowel preparation quality was assessed using the Boston Bowel Preparation Scale (BBPS) by two endoscopists and a nurse present during the procedure. Results: We randomized 150 patients (74 PEG-3350+SD+B and 76 PEG-AA). The PEG-AA group had significantly higher BBPS scores in the right colon by Endoscopist 1, Nurse, and Endoscopist 2 (p 0.005,